Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMPR1B | O00238 | 4/20 | 0.39 |
| ▸ | BMPR1A | P36894 | 4/20 | 0.39 |
| ▸ | ACVRL1 | P37023 | 4/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 4/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.39 |
| ▸ | CTSC | P53634 | 11/20 | 0.38 |
| ▸ | CTSK | P43235 | 9/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.34 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26621569 | 0.75 | BMPR1B (0.42) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL30296573 | 0.72 | AHR (0.49) | BRD4CREBBPTDP2 | |
| SCHEMBL26457138 | 0.72 | AHR (0.49) | BRD4CREBBPTDP2 | |
| SCHEMBL22643366 | 0.72 | TRIM24 (0.42) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL30296424 | 0.72 | HRH3 (0.45) | — | |
| SCHEMBL22642947 | 0.72 | CTSC (0.43) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL31207403 | 0.71 | BRD4 (0.44) | BRD4CREBBP | |
| SCHEMBL19155004 | 0.70 | CHRM1 (0.48) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL19368465 | 0.70 | CTSC (0.48) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL1924307 | 0.69 | SRD5A1 (0.42) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-11-07 | — | — | US | disclosed |
| EP-4419203-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| CN-118451080-A | Tricyclic GPR65 modulators | 帕蒂奥斯治疗有限公司 | 2024-08-06 | — | — | CN | disclosed |
| WO-2023067322-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | GPR65, GPR3, NR1H2 | BMPR1B 1778/4885BMPR1A 1095/4885ACVRL1 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.